サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1404644

細胞リプログラミングの市場規模、シェア、動向分析レポート：技術別、用途別、最終用途別、地域別、セグメント別予測、2024年～2030年

Cell Reprogramming Market Size, Share & Trends Analysis Report By Technology (Episomal Reprogramming, mRNA Reprogramming), By Application (Therapeutic, Research), By End-use, By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 119 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
細胞リプログラミングの市場規模、シェア、動向分析レポート：技術別、用途別、最終用途別、地域別、セグメント別予測、2024年～2030年
出版日: 2023年11月10日
発行: Grand View Research
ページ情報: 英文 119 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞リプログラミング市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の細胞リプログラミング市場規模は2030年までに6億6,420万米ドルに達し、2024年から2030年までのCAGRは8.52％で成長すると予測されています。

がん研究における細胞リプログラミングの採用の増加や細胞リプログラミングに対する注目の高まりなどの要因が市場成長を促進すると予想されます。また、主要企業間の共同研究やパートナーシップの重視が市場成長を後押しすると予想されます。mRNAリプログラミング技術の進歩により、体組織を用いた臨床グレードのヒトiPS細胞の迅速かつ安全で効率的な作製が可能になります。さらに、mRNAはサイズが小さいため、トランスフェクションプロセスは他の初期化ベクターよりも簡単です。リプログラミングが困難なサンプルを利用する場合、mRNAリプログラミングはリプログラミング効率を1％向上させる。

さらに、この方法は体組織から高品質のヒトiPS細胞をより迅速かつ安全に作製できるため、mRNA初期化技術の需要が高まっています。さらに、ヒト幹細胞をナイーブな状態に再プログラムする能力もあり、最も初期の発生段階を再現できます。例えば、2022年3月、バブラハム研究所の研究者たちは、この初期化プロセスを促進する重要な因子を特定しました。この新たな知見は、研究者にとってナイーブ多能性幹細胞の生成を合理化し、迅速化するものです。さらに、細胞の初期化は、政府や公的資金による大きな後押しを受けて成長しています。このような支援は、特に医療への応用の可能性という点で、ヘルスケア分野に様々な利点をもたらすことへの反応です。

さらに、細胞リプログラミングは最近、研究者によって研究室からクリニックへと再配置されています。この変化は、再生医療、疾患モデリング、薬物毒性・創薬に関連する研究など、様々な臨床・学術研究において顕著です。細胞リプログラミングの臨床的有用性は、特に再生医療において顕著です。細胞リプログラミングによる革新的な製品開発を目指した戦略的イニシアチブの増加は、研究・学術機関セグメントの成長によるものです。例えば、California Institute for Regenerative Medicine（カリフォルニア再生医療研究所）は、細胞リプログラミングを臨床に焦点を当てた治療応用に進めるための研究グループに資金を提供しています。

細胞リプログラミング市場レポートハイライト

  • mRNAリプログラミング技術セグメントは、体組織から高品質のヒトiPS細胞を作製する一方で、使いやすさ、スピード、安全性、効率性により、2023年には32.67%の最大の売上シェアを占めました。
  • 研究用途セグメントは、2023年に67.41%のシェアで市場をリードしました。成長を牽引する主な要因のひとつは、幹細胞を用いた細胞リプログラミングの分野で進行中の調査です。
  • 研究・学術機関の最終用途セグメントは、2023年に67.41%の売上シェアを占めました。この成長は、再生治療、疾患モデリング、薬物毒性/創薬研究を含む様々な臨床・学術研究イニシアティブにおける細胞リプログラミングの利用によるものです。
  • 北米は、この地域の主要プレイヤーの存在により、2023年の売上高シェア38.65%で世界の業界を支配しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
  • 市場力学
  • 業界分析ツール

第4章 技術ビジネス分析

  • 細胞リプログラミング市場：技術の変動分析
  • センダイウイルスによるリプログラミング
  • mRNAのリプログラミング
  • エピソームリプログラミング
  • その他

第5章 用途ビジネス分析

  • 細胞リプログラミング市場：用途の変動分析
  • 研究
  • 治療

第6章 最終用途ビジネス分析

  • 細胞リプログラミング市場：最終用途の変動分析
  • 研究および学術機関
  • バイオテクノロジーおよび製薬会社

第7章 地域ビジネス分析

  • 地域別の細胞リプログラミング市場シェア、2022年および2030年
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 企業の分類
  • 戦略マッピング
  • 企業の市況分析、2022年
  • 企業プロファイル・一覧表
    • Thermo Fisher Scientific, Inc.
    • Allele Biotech
    • ALSTEM
    • STEMCELL Technologies Inc.
    • Merck KGaA
    • Bio-Techne
    • REPROCELL
    • Lonza
    • FUJIFILM Corporation（Fujifilm Cellular Dynamics）
    • Mogrify Limited
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 4 Global Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 5 Global Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 6 Global Cell Reprogramming Market, By Region, 2018 - 2030 (USD Million)
  • Table 7 North America Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 9 North America Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 10 North America Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 14 Canada Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 17 Europe Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 19 Europe Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 21 UK Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 22 UK Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 23 UK Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 24 Germany Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 25 Germany Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 26 Germany Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 27 France Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 28 France Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 29 France Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 30 Spain Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 31 Spain Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 32 Spain Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 33 Italy Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 34 Italy Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 35 Italy Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 36 Denmark Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 37 Denmark Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 38 Denmark Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 39 Norway Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 40 Norway Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 41 Norway Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 42 Sweden Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 43 Sweden Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 44 Sweden Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 49 China Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 50 China Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 51 China Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 52 Japan Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 53 Japan Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 54 Japan Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 55 India Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 56 India Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 57 India Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 58 South Korea Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 59 South Korea Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 60 South Korea Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 61 Australia Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 62 Australia Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 63 Australia Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 64 Thailand Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 65 Thailand Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 66 Thailand Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 67 Latin America Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 68 Latin America Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 69 Latin America Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 70 Latin America Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 71 Brazil Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 72 Brazil Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 73 Brazil Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 74 Mexico Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 75 Mexico Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 76 Mexico Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 77 Argentina Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 78 Argentina Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 79 Argentina Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 80 MEA Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 MEA Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 82 MEA Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 83 MEA Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 84 South Africa Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 85 South Africa Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 86 South Africa Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 87 UAE Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 88 UAE Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 89 UAE Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cell Reprogramming market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 PESTEL analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global cell reprogramming market: Technology outlook and key takeaways
  • Fig. 15 Global cell reprogramming market: Technology movement analysis
  • Fig. 16 Global cell reprogramming market, for sendai virus-based reprogramming, 2018 - 2030 (USD Million)
  • Fig. 17 Global cell reprogramming market, for mRNA reprogramming, 2018 - 2030 (USD Million)
  • Fig. 18 Global cell reprogramming market, for episomal reprogramming, 2018 - 2030 (USD Million)
  • Fig. 19 Global cell reprogramming market, for others, 2018 - 2030 (USD Million)
  • Fig. 20 Global cell reprogramming market: Application outlook and key takeaways
  • Fig. 21 Global cell reprogramming market: Application movement analysis
  • Fig. 22 Global cell reprogramming market, for research, 2018 - 2030 (USD Million)
  • Fig. 23 Global cell reprogramming market, for therapeutic, 2018 - 2030 (USD Million)
  • Fig. 24. Global cell reprogramming market: End-use outlook and key takeaways
  • Fig. 25 Global cell reprogramming market: End-use movement analysis
  • Fig. 26 Global cell reprogramming market, for research & academic institutes, 2018 - 2030 (USD Million)
  • Fig. 27 Global cell reprogramming market, for biotechnology & pharmaceutical companies, 2018 - 2030 (USD Million)
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 Regional outlook, 2022 & 2030
  • Fig. 30 North America cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Key country dynamics
  • Fig. 32 U.S. cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Key country dynamics
  • Fig. 34 Canada cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany Key country dynamics
  • Fig. 37 Germany cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Key country dynamics
  • Fig. 39 UK cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 40 France Key country dynamics
  • Fig. 41 France cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Key country dynamics
  • Fig. 43 Italy cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain Key country dynamics
  • Fig. 45 Spain cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark Key country dynamics
  • Fig. 47 Denmark cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden Key country dynamics
  • Fig. 49 Sweden cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway Key country dynamics
  • Fig. 51 Norway cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan Key country dynamics
  • Fig. 54 Japan cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 55 China Key country dynamics
  • Fig. 56 China cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 57 India Key country dynamics
  • Fig. 58 India cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia Key country dynamics
  • Fig. 60 Australia cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea Key country dynamics
  • Fig. 62 South Korea cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand Key country dynamics
  • Fig. 64 Thailand cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil Key country dynamics
  • Fig. 67 Brazil cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico Key country dynamics
  • Fig. 69 Mexico cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina Key country dynamics
  • Fig. 71 Argentina cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East and Africa cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 73 South Africa Key country dynamics
  • Fig. 74 South Africa cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 75 Saudi Arabia Key country dynamics
  • Fig. 76 Saudi Arabia cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 77 UAE Key country dynamics
  • Fig. 78 UAE cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait Key country dynamics
  • Fig. 80 Kuwait cell reprogramming market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-966-2

Cell Reprogramming Market Growth & Trends:

The global cell reprogramming market size is expected to reach USD 664.2 million by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 8.52% from 2024 to 2030. Factors, such as increasing adoption of cell reprogramming in cancer research and growing focus on cell reprogramming, are expected to drive market growth. In addition, emphasis on collaborations and partnerships among key players is anticipated to boost market growth. Advancements in the mRNA reprogramming technique allow rapid, safe, and efficient generation of clinical-grade human iPS cells using somatic tissue. In addition, as mRNA is lower in size, the transfection process is simpler than other reprogramming vectors. When utilizing difficult-to-reprogram samples, mRNA reprogramming improves reprogramming efficiency by 1%.

Furthermore, this method can generate high-quality human iPS cells from somatic tissue more rapidly and safely, which increases the demand for mRNA reprogramming technology. Furthermore, there is the capability to reprogram human stem cells back to a naive state, allowing replication of the earliest developmental stages. For instance, in March 2022, researchers at the Babraham Institute identified key factors facilitating this reprogramming process. This new knowledge streamlines and expedites the generation of naive pluripotent stem cells for researchers. Moreover, cell reprogramming is experiencing growth due to significant government and public funding. This backing is a response to various benefits it offers to the healthcare sector, particularly in terms of its potential applications in medicine.

Furthermore, cell reprogramming has recently been repositioned from the lab to clinic by researchers. This shift is prominent in various clinical & academic research initiatives, encompassing regenerative medicine, disease modeling, and studies related to medication toxicity & drug discovery. The clinical utility of cell reprogramming, especially in regenerative medicine, has been significant. Increased strategic initiatives aimed at innovative product development through cell reprogramming is due to a growth in the research and academic institute segment. For instance, the California Institute for Regenerative Medicine funded research groups to advance cellular reprogramming into therapeutic applications with a clinical focus.

Cell Reprogramming Market Report Highlights:

  • The mRNA reprogramming technology segment held the largest revenue share of 32.67% in 2023 due to the ease of use, speed, safety, and efficiency while generating high-quality human iPS cells from somatic tissue
  • The research application segment led the market with a share of 67.41% in 2023. One of the main factors driving its growth include ongoing research in the field of cell reprogramming using stem cells
  • The research & academic institute end-use segment held a revenue share of 67.41% in 2023. The growth is due to usage of cell reprogramming in a various clinical & academic research initiatives, including those involving regenerative therapies, disease modeling, and drug toxicity/drug discovery studies
  • North America dominated the global industry in 2023 with a revenue share of 38.65% owing to the presence of key players in this region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Information Analysis
    • 1.2.2. Market Platform & Data Visualization
    • 1.2.3. Data Validation & Publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Platform & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing focus on cell reprogramming
      • 3.2.1.2. Increasing adoption of cell reprogramming in cancer research
      • 3.2.1.3. Emphasis on collaborations and partnerships among key players
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Challenges associated with iPSCs
      • 3.2.2.2. Limited awareness regarding treatment option
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Cell Reprogramming Market: Technology Movement Analysis
  • 4.2. Sendai Virus-based Reprogramming
    • 4.2.1. Sendai Virus-based Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.3. mRNA Reprogramming
    • 4.3.1. mRNA Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.4. Episomal Reprogramming
    • 4.4.1. Episomal Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Reprogramming Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Cell Reprogramming Market: Application Movement Analysis
  • 5.2. Research
    • 5.2.1. Research Market, 2018 - 2030 (USD Million)
  • 5.3. Therapeutics
    • 5.3.1. Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. Cell Reprogramming Market: End-use Movement Analysis
  • 6.2. Research & Academic Institutes
    • 6.2.1. Research & Academic Institutes Market, 2018 - 2030 (USD Million)
  • 6.3. Biotechnology & Pharmaceutical Companies
    • 6.3.1. Biotechnology & Pharmaceutical Companies Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Cell Reprogramming Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. U.S. Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Canada Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. UK Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Germany Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. France Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Italy Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Spain Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Denmark Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Sweden Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Norway Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Japan Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. China Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. India Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Australia Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Thailand Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. South Korea Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Brazil Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Mexico Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Argentina Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. South Africa Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Saudi Arabia Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. UAE Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Kuwait Cell Reprogramming Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2022
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific, Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Allele Biotech
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. ALSTEM
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. STEMCELL Technologies Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Merck KGaA
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Bio-Techne
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. REPROCELL
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Lonza
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. FUJIFILM Corporation (Fujifilm Cellular Dynamics)
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Mogrify Limited
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives